Ocrelizumab injection for children with relapsing-remitting multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 10 and 17 years old
- You weigh at least 55 pounds
- You have been diagnosed with relapsing-remitting multiple sclerosis
- Your MS has been stable for at least 30 days before the study starts
- You have had all recommended childhood vaccines
- You have not had certain MS treatments before (like certain immune-suppressing drugs or other B-cell therapies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This trial tests whether adding a new medication, RO7268489, to the standard treatment ocrelizumab (Ocrevus) can help people with progressive forms of multiple sclerosis (MS) by slowing disability progression. The trial will evaluate the safety and effectiveness of this combination approach.
Hear when a new Relapsing-remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.